| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNH1 |
| Uniprot No | P13489 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-461aa |
| 氨基酸序列 | SLDIQSLDIQCEELSDARWAELLPLLQQCQVVRLDDCGLTEARCKDISSALRVNPALAELNLRSNELGDVGVHCVLQGLQTPSCKIQKLSLQNCCLTGAGCGVLSSTLRTLPTLQELHLSDNLLGDAGLQLLCEGLLDPQCRLEKLQLEYCSLSAASCEPLASVLRAKPDFKELTVSNNDINEAGVRVLCQGLKDSPCQLEALKLESCGVTSDNCRDLCGIVASKASLRELALGSNKLGDVGMAELCPGLLHPSSRLRTLWIWECGITAKGCGDLCRVLRAKESLKELSLAGNELGDEGARLLCETLLEPGCQLESLWVKSCSFTAACCSHFSSVLAQNRFLLELQISNNRLEDAGVRELCQGLGQPGSVLRVLWLADCDVSDSSCSSLAATLLANHSLRELDLSNNCLGDAGILQLVESVRQPGCLLEQLVLYDIYWSEEMEDRLQALEKDKPSLRVIS |
| 预测分子量 | 53.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNH1重组蛋白的参考文献示例(内容为模拟创作，仅供参考)：
---
1. **文献名称**: *Expression and Purification of Recombinant Human RNH1 in E. coli*
**作者**: Zhang, L., et al.
**摘要**: 该研究报道了在大肠杆菌系统中高效表达重组人源RNH1蛋白的方法，通过优化表达条件和亲和层析技术实现了蛋白的高纯度制备，并验证了其对核糖核酸酶(RNase A)的抑制活性。
2. **文献名称**: *Structural Insights into the Ribonuclease Inhibitor RNH1 by X-ray Crystallography*
**作者**: Johnson, R.B., & Smith, T.K.
**摘要**: 通过X射线晶体学解析了重组RNH1蛋白的三维结构，揭示了其富含亮氨酸重复序列的独特折叠方式以及与RNase结合的关键氨基酸残基，为理解其抑制机制提供结构基础。
3. **文献名称**: *RNH1 Modulates RNA Stability in Cancer Cells: Implications for Gene Regulation*
**作者**: Chen, H., et al.
**摘要**: 研究利用重组RNH1蛋白探究其在癌细胞中的功能，发现过表达RNH1可通过抑制RNase活性维持特定mRNA稳定性，影响肿瘤相关基因表达，提示其潜在抗癌治疗价值。
4. **文献名称**: *Development of a High-Throughput Screening Assay for RNH1 Inhibitors Using Recombinant Protein*
**作者**: Müller, S., et al.
**摘要**: 基于重组RNH1蛋白建立了高通量药物筛选平台，用于发现靶向RNH1-RNase相互作用的小分子抑制剂，为开发新型RNA代谢调控药物奠定基础。
---
请注意，上述文献为示例性质，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
**Background of RNH1 Recombinant Protein**
RNH1. also known as ribonuclease H1. is an endonuclease that specifically hydrolyzes the RNA strand in RNA-DNA hybrids, a critical activity in DNA replication, repair, and transcription. It plays a vital role in maintaining genome stability by resolving R-loops (three-stranded nucleic acid structures) and processing Okazaki fragments during DNA replication. Dysregulation of RNH1 has been implicated in diseases such as cancer and neurodegenerative disorders, highlighting its biological significance.
The recombinant form of RNH1 is engineered using molecular cloning techniques, typically expressed in *E. coli* or eukaryotic systems to ensure proper folding and enzymatic activity. Purification methods like affinity chromatography yield high-purity protein, which retains native functionality. Recombinant RNH1 is widely used in *in vitro* studies to investigate DNA repair mechanisms, reverse transcription processes (e.g., in HIV research), and R-loop dynamics.
Structurally, RNH1 contains a hybrid-binding domain for substrate recognition and a catalytic domain with conserved acidic residues essential for Mg²⁺-dependent cleavage. Its recombinant version enables detailed biochemical and structural analyses, including crystallography and drug discovery assays. Researchers also utilize it in biotechnology applications, such as reducing RNA contamination in cDNA synthesis and improving PCR efficiency.
Overall, recombinant RNH1 serves as a versatile tool for both basic research and therapeutic development, bridging insights into nucleic acid metabolism and disease pathology.
×
